SCHEMBL10153609

SCHEMBL10153609

O=C(Nc1ccccc1)C1C(=O)N(O)C(=O)c2ccccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
LMNA P02545 2/20 0.47
GAA P10253 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
SRC P12931 2/20 0.46
EGFR P00533 1/20 0.46
HDAC6 Q9UBN7 2/20 0.44
TOP2A P11388 1/20 0.44
SLC22A12 Q96S37 1/20 0.44
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
NCOR2 Q9Y618 1/20 0.41
POLB P06746 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31653962 1.00 MEN1 (0.47) MEN1KMT2ALMNAGAASMN1; SMN2
SCHEMBL9958675 0.89 KMT2A (0.50) MEN1KMT2ALMNAGAASMN1; SMN2
SCHEMBL9959487 0.86 HTT (0.43) MEN1KMT2AGAAPOLBRAB9A
SCHEMBL8280317 0.84 MEN1 (0.59) MEN1KMT2ALMNAGAASMN1; SMN2
SCHEMBL9958705 0.84 HDAC4 (0.62) MEN1KMT2ALMNAGAASMN1; SMN2
SCHEMBL19380274 0.82 HDAC4 (0.44) MEN1KMT2ALMNAGAASMN1; SMN2
SCHEMBL20777886 0.82 MEN1 (0.37) MEN1KMT2ALMNAGAASMN1; SMN2
SCHEMBL10153606 0.82 KCNA5 (0.48) MEN1KMT2ALMNAGAASMN1; SMN2
SCHEMBL31653994 0.82 KCNA5 (0.48) MEN1KMT2ALMNAGAASMN1; SMN2
SCHEMBL11789850 0.82 ALDH1A1 (0.43) MEN1KMT2ALMNAGAAHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190070165-A1 N-HYDROXYISOQUINOLINEDIONE INHIBITORS OF HBV REPLICATION SAINT LOUIS UNIVERSITY (US) 2019-03-07 US disclosed
WO-2017161133-A1 N-HYDROXYISOQUINOLINEDIONE INHIBITORS OF HBV REPLICATION SAINT LOUIS UNIVERSITY (US) 2017-09-21 WO disclosed
WO-2012085003-A1 2-HYDROXYISOQUINOLINE-1,3(2H,4H)-DIONES AND RELATED COMPOUNDS USEFUL AS HIV REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190070165-A1 N-HYDROXYISOQUINOLINEDIONE INHIBITORS OF HBV REPLICATION HCCS, HAVCR2, HDGF MEN1 4053/4885KMT2A 2169/4885LMNA 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.